Research Article | Open Access | 10.31586/Cancer.0403.05

Role of CTSC in Glioblastoma Based on Oncomine and TCGA Database


Background and objective Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM.

Methods The information about CTSC in Oncomine database was collected and analyzed twice. The role of CTSC in GBM was meta-analyzed. The expression of CTSC in glioma cell lines was retrieved by CCLE database, and the survival of patients was analyzed by TCGA database.

Results A total of 1,459 different types of CTSC were collected in Oncomine database, 134 of which had statistical differences in CTSC expression, 89 of which had increased CTSC expression and 45 of which had decreased CTSC expression. A total of 50 studies involving the expression of CTSC in GBM cancer and normal tissues included 1,189 samples.

Compared with the control group, CTSC was highly expressed in GBM (P < 0.05). Moreover, CTSC was highly expressed in glioma cell lines. There was a correlation between the expression of CTSC and the overall survival rate of GBM. The overall survival rate of patients with high expression of CTSC was worse, while the prognosis of patients with low expression of SPC24 was better (P < 0.05).

Conclusion Through the in-depth mining of oncomine gene chip database, we propose that CTSC is highly expressed in GBM tissues and is related to the prognosis of GBM, which may provide an important theoretical basis for the treatment of glioma.


Figure 1 of 4


Kirkpatrick JP, Laack NN, Shih HA, Gondi V. Management of GBM: a problem of local recurrence. J Neurooncol 2017;134:487-93.
Jayaraman A, Jamil K, Khan HA. Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci 2015;22:610-22.
Hou W, Sun H, Ma Y, Liu C, Zhang Z. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors. J Med Chem 2019.
Fan W, Zhang W, Alshehri S, Neeley TR, Garrison JC. Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor. Eur J Med Chem 2019;177:386-400.
Shoaib M, Ansari AA, Haq F, Ahn SM. IPCT: Integrated Pharmacogenomic Platform of Human Cancer Cell Lines and Tissues. Genes (Basel) 2019;10.
Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer 2014;14:970.
Tang Y, He W, Wei Y, Qu Z, Zeng J, Qin C. Screening key genes and pathways in glioma based on gene set enrichment analysis and meta-analysis. J Mol Neurosci 2013;50:324-32.
Zuo X, Hou Q, Jin J, et al. Inhibition of Cathepsins B Induces Neuroprotection Against Secondary Degeneration in Ipsilateral Substantia Nigra After Focal Cortical Infarction in Adult Male Rats. Front Aging Neurosci 2018;10:125.
Lupo KB, Matosevic S. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy. Cancers (Basel) 2019;11.
Yan H, Zhou HF, Akk A, et al. Neutrophil Proteases Promote Experimental Abdominal Aortic Aneurysm via Extracellular Trap Release and Plasmacytoid Dendritic Cell Activation. Arterioscler Thromb Vasc Biol 2016;36:1660-9.
Doughty MJ, Gruenstein EI. Cell growth and substrate effects on characteristics of a lysosomal enzyme (cathepsin C) in Duchenne muscular dystrophy fibroblasts. Biochem Cell Biol 1987;65:617-25.
Gelman BB, Papa L, Davis MH, Gruenstein E. Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy. J Clin Invest 1980;65:1398-406.
Ruffell B, Affara NI, Cottone L, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013;27:2086-98.
Article metrics
Views 183
Downloads 133
Citations 0
PDF View Full-Text